Heart & Vascular Care in China
More structural heart interventions than anywhere on Earth — with global-first credentials in myocarditis, gene therapy, and mechanical circulatory support.
For decades, families across the Gulf, North Africa, and Asia traveled to the United States, Germany, or Singapore for complex cardiac care. That's changing.
China's top cardiac centers now perform more structural heart interventions than anywhere else on Earth, with three distinct global-first credentials: the “China Protocol” for fulminant myocarditis (pioneered at Tongji and scaled nationally), the world's only commercially approved gene therapy for critical limb ischemia (NL003), and the world's smallest implantable LVAD (CorHeart 6). All delivered at a fraction of US cost, often with same-week appointments.
MediPath coordinates pre-arrival expert review, hospital matching, and end-to-end care.
China-originated cardiovascular firsts — and faster access to global therapies.
China's cardiovascular pipeline pairs China-developed PCSK9 antibodies and the world's only approved gene therapy for critical limb ischemia with earlier, lower-cost access to US-developed cardiomyopathy and rare-disease drugs.
NL003
the world's only gene therapy for critical limb ischemia — NDA accepted by China's NMPA, ahead of expected US approval[R7-R8]
Q8W
recaticimab — the world's first PCSK9 antibody approved for dosing once every eight weeks[R5-R6]
Dec 2025
aficamten (oHCM) approved by NMPA among the first markets globally — US list price ~$108,400/yr[R9-R10]
Procedural volume that builds judgment, not just technique.
China performs more catheter-based cardiac interventions than any other country — the accumulated experience behind a new global standard for fulminant myocarditis and the first Chinese cardiology technique in international guidelines.
3.7–8.1%
in-hospital mortality for fulminant myocarditis under the China Protocol, down from 45–55% with conventional care[R16]
ESC guidelines
PADN for pulmonary hypertension — the first Chinese cardiology technique incorporated into international consensus[R17]
~19,000
one-stop ablation + LAAO procedures performed in China in 2025[R14-R15]
From import-dependent to globally validated.
Chinese cardiovascular technology now carries global clinical validation — from the first Chinese stent in The Lancet to a TAVR system licensed to Edwards Lifesciences and the world's smallest implantable LVAD.
Lancet 2018
Firehawk — the first Chinese-manufactured drug-eluting stent with clinical data in The Lancet, non-inferior to the global standard[R26]
ESC IIa
QFR wire-free FFR — the first Chinese cardiovascular technology in ESC clinical guidelines[R19-R20]
90g
CorHeart 6 — the world's smallest and lightest implantable LVAD; 1,200+ implants as of 2026[R25]
Signature Institutions for Heart & Vascular Care in China
Fuwai Hospital
中国医学科学院阜外医院
Beijing
Cardiac surgery, congenital heart, interventional cardiology, TAVR
Beijing Anzhen Hospital
首都医科大学附属北京安贞医院
Beijing
Robotic mitral valve repair, coronary bypass, structural heart disease
Zhongshan Hospital
复旦大学附属中山医院
Shanghai
Comprehensive cardiac care, valve surgery, electrophysiology
Request a Heart & Vascular Case Review
Share your diagnosis, imaging, catheterization or echo reports, medication history, and current goals. Our team can help identify whether China offers a relevant second opinion, interventional or surgical pathway, device option, or faster access to a therapy for your condition.